RYMTI DIN 02530287
Status: Approved
Holder: LUPIN PHARMA CANADA LIMITED
Health Canada record
| Active ingredient(s) | ETANERCEPT 25 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L04AB01 ETANERCEPT |
|---|
| Original market date | |
|---|
| Current status date | 31-Aug-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Lupin Pharma Canada Limited — licence 102119, currently licensed, last inspection rating C (2025-07-22).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ETANERCEPT
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02455331 | BRENZYS | SAMSUNG BIOEPIS CO., LTD | Solution | ETANERCEPT 50 MG | Marketed |
| 02455323 | BRENZYS | SAMSUNG BIOEPIS CO., LTD | Solution | ETANERCEPT 50 MG | Marketed |
| 02274728 | ENBREL | IMMUNEX CORPORATION | Solution | ETANERCEPT 50 MG | Marketed |
| 02462869 | ERELZI | SANDOZ CANADA INCORPORATED | Solution | ETANERCEPT 50 MG | Marketed |
| 02462850 | ERELZI | SANDOZ CANADA INCORPORATED | Solution | ETANERCEPT 50 MG | Marketed |
| 02462877 | ERELZI | SANDOZ CANADA INCORPORATED | Solution | ETANERCEPT 25 MG | Marketed |
| 02530295 | RYMTI | LUPIN PHARMA CANADA LIMITED | Solution | ETANERCEPT 50 MG | Marketed |
| 02530309 | RYMTI | LUPIN PHARMA CANADA LIMITED | Solution | ETANERCEPT 50 MG | Marketed |
| 02242903 | ENBREL | IMMUNEX CORPORATION | Liquid; Kit; Powder For Solution | ETANERCEPT 25 MG; WATER 1 ML | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 28898 | 2022-08-31 | New Drug Submission (NDS) | |
Request a quote for RYMTI
How to read a Canadian DIN record